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Effect of ten-valent pneumococcal conjugate vaccine on 
invasive pneumococcal disease and nasopharyngeal carriage 
in Kenya: a longitudinal surveillance study
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Angela Karani, Donald O Akech, Mark Otiende, Tahreni Bwanaali, Jackline Wafula, Christine Mataza, Edward Mumbo, Collins Tabu, 
Maria Deloria Knoll, Evasius Bauni, Kevin Marsh, Thomas N Williams, Tatu Kamau, Shahnaaz K Sharif, Orin S Levine, J Anthony G Scott
Summary
Background Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of age was 
introduced in Kenya in January, 2011, accompanied by a catch-up campaign in Kilifi County for children aged younger 
than 5 years. Coverage with at least two PCV10 doses in children aged 2–11 months was 80% in 2011 and 84% in 2016; 
coverage with at least one dose in children aged 12–59 months was 66% in 2011 and 87% in 2016. We aimed to assess 
PCV10 effect against nasopharyngeal carriage and invasive pneumococcal disease (IPD) in children and adults in 
Kilifi County.
Methods This study was done at the KEMRI-Wellcome Trust Research Programme among residents of the Kilifi 
Health and Demographic Surveillance System, a rural community on the Kenyan coast covering an area of 891 km². 
We linked clinical and microbiological surveillance for IPD among admissions of all ages at Kilifi County Hospital, 
Kenya, which serves the community, to the Kilifi Health and Demographic Surveillance System from 1999 to 2016. 
We calculated the incidence rate ratio (IRR) comparing the prevaccine (Jan 1, 1999–Dec 31, 2010) and postvaccine 
(Jan 1, 2012–Dec 31, 2016) eras, adjusted for confounding, and reported percentage reduction in IPD as 1 minus IRR. 
Annual cross-sectional surveys of nasopharyngeal carriage were done from 2009 to 2016.
Findings Surveillance identified 667 cases of IPD in 3 211 403 person-years of observation. Yearly IPD incidence in 
children younger than 5 years reduced sharply in 2011 following vaccine introduction and remained low (PCV10-type 
IPD: 60·8 cases per 100 000 in the prevaccine era vs 3·2 per 100 000 in the postvaccine era [adjusted IRR 0·08, 95% CI 
0·03–0·22]; IPD caused by any serotype: 81·6 per 100 000 vs 15·3 per 100 000 [0·32, 0·17–0·60]). PCV10-type IPD also 
declined in the post-vaccination era in unvaccinated age groups (<2 months [no cases in the postvaccine era], 5–14 years 
[adjusted IRR 0·26, 95% CI 0·11–0·59], and ≥15 years [0·19, 0·07–0·51]). Incidence of non-PCV10-type IPD did not 
differ between eras. In children younger than 5 years, PCV10-type carriage declined between eras (age-standardised 
adjusted prevalence ratio 0·26, 95% CI 0·19–0·35) and non-PCV10-type carriage increased (1·71, 1·47–1·99).
Interpretation Introduction of PCV10 in Kenya, accompanied by a catch-up campaign, resulted in a substantial reduction 
in PCV10-type IPD in children and adults without significant replacement disease. Although the catch-up campaign is 
likely to have brought forward the benefits by several years, the study suggests that routine infant PCV10 immunisation 
programmes will provide substantial direct and indirect protection in low-income settings in tropical Africa.
Funding Gavi, The Vaccine Alliance and The Wellcome Trust of Great Britain.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
The number of pneumococcal deaths in children aged 
1–59 months was estimated at 317 000 globally in 2015, a 
decline of more than 50% from 2000.1 In middle-income 
and high-income countries, inclusion of pneumococcal 
conjugate vaccines (PCVs) in routine infant vaccination 
programmes has led to a substantial reduction in the 
incidence of invasive pneumococcal disease (IPD) caused 
by vaccine serotypes (VTs). In addition, because vaccinated 
children are less likely to carry and transmit VT pneu-
mococci, programmatic use of vaccination in children has 
resulted in a decline in IPD in unvaccinated individuals 
(ie, herd protection).2 Evidence of the effect of PCVs in low- 
income settings is sparse and effect models rely on efficacy 
estimates from randomised controlled trials, not real-
world implementation. Furthermore, there is no evidence 
of the effect of ten-valent PCV (PCV10) conjugated to non-
typeable Haemophilus influenzae on invasive pneumococcal 
disease in Africa, where the greatest burden of deaths 
from pneumococcal disease occur.
61% (82·4 million) of the world’s infants have not 
received PCV; however, dozens of low-income countries 
have introduced PCV or will do so in the coming decade.3 
In 2011, with support from Gavi, the Vaccine Alliance, 
Published Online 
April 15, 2019 
http://dx.doi.org/10.1016/
S0140-6736(18)33005-8
See Online/Comment 
http://dx.doi.org/10.1016/
S0140-6736(19)30039-X 
Epidemiology and 
Demography Department, 
KEMRI-Wellcome Trust 
Research Programme, Centre 
for Geographic Medicine-Coast, 
Kilifi, Kenya (L L Hammitt MD, 
A O Etyang ChB, 
S C Morpeth FRACP, J Ojal PhD, 
A Mutuku MSc, 
N Mturi MRCPCH, J C Moisi PhD, 
I M Adetifa PhD, A Karani BSc, 
D O Akech BSc, M Otiende MSc, 
T Bwanaali MBA, J Wafula BSN, 
E Bauni PhD, 
Prof K Marsh FMedSci, 
Prof T N Williams FMedSci, 
Prof J A G Scott FRCP); Nuffield 
Department of Clinical 
Medicine, University of Oxford, 
Oxford, UK (L L Hammitt, 
S C Morpeth, J C Moisi, 
T Bwanaali, Prof K Marsh, 
Prof J A G Scott); Department 
of International Health, 
Johns Hopkins Bloomberg 
School of Public Health, 
Baltimore, MD, USA 
(L L Hammitt, M D Knoll PhD, 
Prof O S Levine PhD); 
Department of Infectious 
Disease Epidemiology, London 
School of Hygiene & Tropical 
Medicine, London, UK 
(A O Etyang, S C Morpeth, J Ojal, 
I M Adetifa, Prof J A G Scott); 
Pfizer Vaccines, Paris, France 
(J C Moisi); County Health 
Department, Kilifi County, 
Kenya (C Mataza KRCHN, 
E Mumbo BSc); National 
Vaccines and Immunization 
Programme, Ministry of 
Health, Kenya (C Tabu MPH, 
T Kamau MPH, S K Sharif MD); 
Imperial College, London, UK 
(Prof T N Williams); INDEPTH 
Network, Accra, Ghana 
(Prof T N Williams, 
Prof J A G Scott); 
and Bill & Melinda Gates 
Articles
2 www.thelancet.com   Published online April 15, 2019   http://dx.doi.org/10.1016/S0140-6736(18)33005-8
Foundation, Seattle, WA, USA 
(Prof O S Levine)
Correspondence to: 
Dr Laura Hammitt, Department 
of International Health, Johns 
Hopkins Bloomberg School of 
Public Health, Baltimore, 
MD 21231, USA 
lhammitt@jhu.edu
Kenya became one of the first countries in Africa to 
introduce PCV and the first country in Africa to use 
PCV10. PCV10 was introduced in the Kenyan national 
childhood immunisation schedule as a three-dose 
series administered at 6, 10, and 14 weeks of age. There is 
good evidence of the efficacy of PCV9 in African settings, 
but efficacy of PCV10 (Synflorix; GlaxoSmithKline) has 
not been shown.4,5 Furthermore, because of the potential 
for substantial herd protection or for serotype replacement 
disease, the net population benefit of the PCV programme 
in these settings can only be estimated through longi-
tudinal IPD surveillance. This information is essential to 
support realistic cost-effectiveness analyses and sustain 
the commitment of Ministries of Health to the PCV 
programme as countries transition from Gavi support for 
vaccines to self-financing.
Through a collaboration between the Kenyan Ministry of 
Health, Gavi, and the KEMRI-Wellcome Trust Research 
Programme (KWTRP), we used an existing integrated 
demographic, clinical, and microbiological surveillance 
system to do a prospectively designed assessment of 
vaccine effect against nasopharyngeal carriage and IPD in 
children and adults before and after introduction of PCV10 
in the routine infant immunisation programme in Kenya.
Methods
Study design and participants
This study was done at KWTRP among residents of the 
Kilifi Health and Demographic Surveillance System 
(KHDSS), a rural community on the Kenyan coast 
covering an area of 891 km². A census of the KHDSS in 
2000 defined the resident population, and all subsequent 
births, deaths, and migration events were monitored 
by fieldworker visits to every participating household 
at approximately 4-monthly intervals.6 The population 
(179 568 in 1999; 239 392 in 2007; 284 826 in 2016) is 
served by a single government hospital, Kilifi County 
Hospital (KCH). Among women attending antenatal 
clinic at KCH, the prevalence of HIV infection ranged 
between 2·1% and 4·6% during 2005–16 (appendix). The 
prevalence of HIV among children aged up to 5 years in 
Kenya was estimated in 2012 at 1·6%.7 H influenzae type 
b conjugate vaccine was introduced in Kenya in 2001.8 In 
the 12 years before PCV10 introduction, the serotypes 
contained in PCV10 (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 
and 23F) comprised 75% of IPD in children aged up to 
5 years in Kilifi. The protocol was approved by the Oxford 
Tropical Ethical Review Committee (No. 30-10) and the 
Kenya National Ethical Review Committee (SSC1433). 
Adult participants and parents or guardians of all child 
participants provided written informed consent.
Procedures
In January, 2011, the Government of Kenya introduced 
PCV10 into the national immunisation sched ule, 
ad ministered simultaneously with pentavalent vaccine 
(diphtheria–whole cell pertussis–tetanus–hepatitis B–H 
influenzae type b vaccine) at 6, 10, and 14 weeks of age. A 
national catch-up campaign provided three doses of PCV10 
to children aged less than 12 months. As part of the study 
See Online for appendix
Research in context
Evidence before this study
In middle-income and high-income countries, inclusion of 
pneumococcal conjugate vaccines (PCVs) in routine infant 
vaccination programmes has led to a substantial reduction in 
the incidence of invasive pneumococcal disease (IPD) caused by 
vaccine serotypes. However, pneumococcal disease remains a 
leading vaccine-preventable cause of childhood mortality and 
most of these deaths occur in Africa. This study was planned in 
2006, after Gavi, the Vaccine Alliance, made the decision to 
support introduction of PCVs in lower-income countries. It 
aimed to capture the population effect of PCV introduction in 
operational use against IPD and nasopharyngeal carriage. 
Although there are data from The Gambia showing a reduction 
in IPD in young children 5 years after the introduction of 
seven-valent pneumococcal conjugate vaccine and 3 years 
following the introduction of 13-valent pneumococcal 
conjugate vaccine, there are no effect data from low-income 
settings that have adopted ten-valent pneumococcal conjugate 
vaccine (PCV10). In addition, the duration of the study in The 
Gambia was not sufficient to assess the indirect effects of the 
PCV programme. Establishing the population effect of PCV in 
low-resource settings is essential to sustain the commitment of 
Ministries of Health to PCV programmes.
Added value of this study
This study provides the first population-level evidence of the 
effect of a PCV10 programme in a low-income country. In this 
18-year population-based, laboratory-based surveillance study, 
introduction of PCV10 with a catch-up campaign for children 
under 5 years and without a booster dose reduced the 
incidence of PCV10-type IPD in children aged up to 5 years 
(by 92% [95% CI 78–97]) and in unvaccinated age groups (74% 
[41–89] in the 5–14-year age group; 81% [49–93] in the 
15 years and older age group). There was no significant change 
in the incidence of non-PCV10-type IPD. The observed decline 
in PCV10-type IPD is supported by the observed trends in 
vaccine-type pneumococcal carriage.
Implications of all the available evidence
Our study suggests that use of PCV10 in low-income settings 
will lead to substantial health benefits for the whole 
population, not just vaccine recipients. These results will 
underpin policy making in African countries as they confront 
the challenge of continuing PCV programmes independently 
of Gavi.
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design, the Ministry of Health did a catch-up campaign in 
Kilifi County providing up to two doses of PCV10 to 
children aged 12–59 months in two campaigns, beginning 
on Jan 31, 2011 and March 21, 2011, each lasting 1–2 weeks. 
All vaccines were captured by the Kilifi Vaccine Monitoring 
System, a registry in which data clerks at 26 clinics serving 
the KHDSS linked vaccination at the point of delivery to 
the child’s identification in the KHDSS.9
Children admitted to KCH (with the exception of 
patients with trauma or patients admitted for elective 
surgery) were investigated with a blood culture at the time 
of admission from 1999 to 2016.10 Adults (aged ≥15 years) 
admitted to KCH from 2007 to 2016 were investigated 
with a blood culture at the time of admission if there 
were signs or symptoms of invasive bacterial disease (eg, 
history of fever, axillary temperature <36·0°C or >37·5°C, 
signs of focal sepsis).11 Blood was cultured by use of an 
automated BACTEC instrument (BD Diagnostics, USA). 
From 1999 to 2016, apart from a brief change in practice in 
2004–05 (appendix),8 the clinical indications for lumbar 
puncture were impaired consciousness or meningism in 
children younger than 5 years, prostration in children 
younger than 3 years, seizures (other than febrile seizures) 
in children younger than 2 years and suspicion of sepsis 
in children younger than 60 days, or suspected meningo-
encephalitis in adults. Cerebrospinal fluid (CSF) was 
cultured on horse blood and chocolate agar. Admitted 
patients were tested for HIV with two rapid antibody tests 
according to the Kenya national policy.12 Patients were 
treated according to Kenyan Ministry of Health or WHO 
guidelines.
Nasopharyngeal carriage of pneumococci was assessed 
through annual cross-sectional surveys of approximately 
500 KHDSS residents of all ages selected at random from 
the KHDSS population register each year from 
2009 to 2016. The methods are described elsewhere, with 
the exception that flocked swabs (Copan Diagnostics, 
USA) replaced rayon swabs in 2016.13
Isolates of Streptococcus pneumoniae from sterile-site and 
nasopharyngeal swab cultures were identified by optochin 
susceptibility; serotyping was performed by latex agglu-
tination and Quellung reaction. If pneumococcal colonies 
of varying appearance were observed, only those of the 
dominant colony morphology were serotyped. Serogroup 
6 isolates were tested by PCR for confirmation of serotype. 
Invasive isolates from 1999 to 2008 underwent repeat 
confirmatory serotyping by Quellung and multiplex PCR.14 
Invasive isolates from 2008 to 2016 underwent real-time 
confirmatory serotyping by PCR; discordant results were 
resolved by a second PCR. A case of IPD was defined as 
isolation of S pneumoniae from a sterile site culture in an 
individual admitted to KCH who was resident in the 
KHDSS. VT isolates were those belonging to PCV10 
serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F). All 
other serotypes were classified as non-VT. Pneumococcal 
meningitis was defined as isolation of S pneumoniae from 
CSF or isolation of S pneumoniae from blood, accompanied 
by a CSF white blood cell count of at least 50 × 10⁶ cells per L 
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Figure 1: Proportion of children vaccinated with PCV10
(A) 0–11 months of age. (B) 12–23 months of age. (C) 24–59 months of age. (D) 5–9 years of age in the Kilifi Health and Demographic Surveillance System, 2011–16. 
PCV10=ten-valent pneumococcal conjugate vaccine.
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or a ratio of CSF glucose to plasma glucose of less 
than 0·1.15 Pneumococcal pneumonia was defined as a 
case of IPD in a child with cough or difficulty breathing, 
and at least one of the following: lower chest wall 
indrawing, central cyanosis, inability to drink, convulsions, 
lethargy, prostration, or head nodding.16
Statistical analysis
We designated Jan 1, 1999 through Dec 31, 2010, as the 
prevaccine era and Jan 1, 2012 through Dec 31, 2016, as 
the postvaccine era. The year of vaccine introduction, 
2011, was excluded from the analysis of PCV10 effect. We 
calculated the age-stratified incidence of IPD in each year 
as the annual number of cases divided by the mid-year 
population in the KHDSS. We excluded admissions and 
person-years of observation during health-care worker 
strikes (appendix). Unadjusted incidence rate ratios 
(IRRs) were calculated for the postvaccine era compared 
with the prevaccine era by age group by means of negative 
binomial regression because of over-dispersion in the 
data. Possible confounders of the association between 
IPD and vaccine introduction included time (year), 
annual incidence of admissions, malaria admissions (ie, 
presence of malaria parasites by micro scopy), moderate 
or severe malnutrition admissions (among children aged 
<5 years; defined as weight-for-age lower than −2 Z scores 
below the median of the WHO child growth standards),17 
and compliance with reco mmendations for investigation 
by blood culture. Potential confounders with a p value of 
less than 0·1 in univariate analysis were included in the 
multivariable analysis; we used backward stepwise 
regression and excluded variables with a likelihood ratio 
test p value of at least 0·05. We built age-group-specific 
models for IPD caused by any serotype and applied the 
same structure within age group for VT and non-VT IPD. 
The percentage reduction in disease was calculated as 
1 minus the adjusted IRR.
We calculated pneumococcal carriage prevalence ratios 
comparing nasopharyngeal carriage in the prevaccine 
and postvaccine eras as previously described.13 Briefly, 
prevalence ratios were modelled by means of log-
binomial regression; if the models failed to converge we 
used Poisson regression with robust CIs. Adjusted 
prevalence ratios were age standardised to reflect the 
stratified sampling scheme by use of the inverse of the 
sampling ratio as population weights.
The significance of vaccine effect on serotype-specific 
IPD or carriage was tested with a Bonferroni correction 
(ie, for 25 serotypes, the correction was 0·05/25).
STATA 14.0 (Stata Corp, USA) was used for the analysis.
Role of the funding source
The study was funded by Gavi, The Vaccine Alliance and 
The Wellcome Trust. The funders had no role in the 
study design, data analysis, data collection, data inter-
pretation or writing of the report. The corresponding 
author had full access to all the data in the study and had 
final responsibility for the decision to submit the paper 
for publication.
Results
Coverage with PCV10 increased sharply during the catch-
up campaign and slowly thereafter (figure 1; appendix). 
Coverage with at least two PCV10 doses in 2–11-month- 
old infants was 80% by the end of 2011 and 84% by the 
end of 2016; coverage with at least one dose in 
12–59-month-old infants was 66% by the end of 2011 and 
87% by the end of 2016.
Prevaccine era 
(1999–2010) n (%)
Postvaccine era 
(2012–16) n (%)
p value*
Age <5 years
Total admissions 31 422 6323 ··
Mean annual admissions 2618 1264 <0·001
Recommended for blood culture 30 098 (96%) 5691 (90%) <0·001
Blood culture collected† 29 234 (97%) 5353 (94%) <0·001
Culture-confirmed IPD 401 34 ··
Age <24 months 273 (68%) 20 (59%) 0·27
Male 229 (57%) 23 (68%) 0·23
Cultured from blood specimen 390 (97%) 34 (100%) 0·33
Cultured from CSF 71 (18%) 3 (9%) 0·19
Pneumococcal meningitis‡ 78 (19%) 3 (9%) 0·13
HIV-infected§ 25 (20%) 4 (15%) 0·55
Died during the episode 70 (17%) 11 (32%) 0·03
Age 5–14 years
Total admissions 5296 2060 ··
Mean annual admissions 441 412 0·61
Recommended for blood culture 4483 (85%) 1592 (77%) <0·001
Blood culture collected† 4200 (94%) 1438 (90%) <0·001
Culture-confirmed IPD 127 22 ··
Male 66 (52%) 10 (45%) 0·57
Cultured from blood specimen 121 (95%) 21 (95%) 0·97
Cultured from CSF 31 (24%) 2 (9%) 0·11
Pneumococcal meningitis‡ 37 (29%) 4 (18%) 0·29
HIV-infected§ 7 (23%) 5 (36%) 0·39
Died during the episode 30 (24%) 2 (9%) 0·13
Age ≥15 years
Total admissions 5332 5163 ··
Mean annual admissions 1326 1032 0·10
Recommended for blood culture 5048 (95%) 4597 (89%) <0·001
Blood culture collected† 2107 (42%) 1875 (41%) 0·34
Culture-confirmed IPD 30 26 ··
Male 12 (40%) 11 (42%) 0·86
Cultured from blood specimen 29 (97%) 23 (88%) 0·23
HIV-infected§ 4 (33%) 14 (64%) 0·09
Died during the episode 12 (40%) 12 (46%) 0·64
KHDSS=Kilifi Health and Demographic Surveillance System. IPD=invasive pneumococcal disease. CSF=cerebrospinal 
fluid. *p value computed by t test for comparison of means and χ² for comparison of percentages. †Among those 
recommended for blood culture. ‡Defined as isolation of Streptococcus pneumoniae from CSF or isolation of 
S pneumoniae from blood, accompanied by a CSF white blood cell count of ≥50 × 10⁶ cells per L or greater, or a ratio of 
CSF glucose to plasma glucose <0·1. §Among those with HIV status ascertained.15
Table 1: Invasive pneumococcal disease among children and adults in the KHDSS admitted to the Kilifi 
County Hospital, in the prevaccine and postvaccine eras
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During the 18-year surveillance period, we identified 
667 cases of IPD in 3 211 403 person-years of observation 
among KHDSS residents (appendix). The proportion of 
IPD cases detected by culture of blood or CSF and the 
proportion with HIV infection did not change between 
the prevaccine and postvaccine eras (table 1). Among 
children younger than 5 years, the median age of IPD 
cases was 14 months (IQR 7–30) in the prevaccine era 
and 20 months (IQR 6–38) in the PCV10 era. Throughout 
the 18-year surveillance period, several indicators 
suggested large improvements in the overall health of 
the population (appendix).
Among children younger than 5 years, the annual 
incidence of VT-IPD declined from 60·8 per 100 000 in 
the prevaccine era to 3·2 per 100 000 in the postvaccine 
era (table 2; figure 2; appendix) representing a reduction 
of 92% (95% CI 78–97; adjusted for year). The average 
annual number of VT-IPD cases fell from 25 (IQR 16–33) 
in the prevaccine era to 1 (IQR 1–2) in the postvaccine 
era. Seven children had VT-IPD in the postvaccine era: 
two were unvaccinated and five were age-appropriately 
vaccinated (appendix). Of the five children who 
developed VT-IPD after receipt of PCV10, two were 
noted to have malnutrition. A decline in incidence was 
observed for all PCV10 serotypes, and this was 
significant for serotypes 1 and 14, the most common 
serotypes in the prevaccine era. Serotype 1, in addition 
to causing a steady background of IPD, also caused 
occasional epidemics of IPD in Kilifi—for example, in 
2010. Introduction of PCV10 effectively terminated this 
epidemic and resulted in the near-elimination of 
serotype 1 IPD (appendix). The incidence of non-VT 
IPD did not increase following introduction of PCV10 
(IRR 1·31; 95% CI 0·65–2·64; table 2). To assess 
whether classification of serotype 6A as a non-VT 
masked our ability to detect an increase in non-VT IPD, 
we did a sensitivity analysis in which 6A was excluded 
from the non-VT group; results were similar (IRR 1·46; 
95% CI 0·62–3·41). Overall in children younger than 
5 years, use of PCV10 led to a 68% (95% CI 40–83) 
reduction in the incidence of all-serotype IPD, and an 
85% (95% CI 66–93) reduction in the incidence of 
bacteraemic pneumococcal pneumonia.
Among children too young to be vaccinated 
(ie, <2 months of age), the incidence of VT-IPD declined 
from 173·2 per 100 000 in the prevaccine era to 0·0 
per 100 000 in the postvaccine era. A significant decline 
in the incidence of VT-IPD was also observed among 
individuals aged 5–14 years (74% reduction, 95% CI 
41–89; adjusted for blood culture ascertainment), and 
Prevaccine era (1999–2010)* Postvaccine era (2012–16) Postvaccine vs prevaccine era
n Incidence per 100 000 
(95% CI)
n Incidence per 100 000 
(95% CI)
IRR† 
(95% CI)
Adjusted IRR‡ 
(95% CI)
IPD caused by any serotype
<2 months 43 240·2 (173·9–323·6) 1 7·9 (0·2–44·0) 0·03 (0·00–0·25) 0·13 (0·01–1·24)
<5 years 401 81·6 (73·8–89·9) 34 15·3 (10·6– 21·40) 0·18 (0·11–0·29) 0·32 (0·17–0·60)
5–14 years 127 15·8 (13·2–18·8) 22 5·5 (3·5–8·4) 0·34 (0·17–0·67) 0·47 (0·24–0·92)
≥15 years 30 6·9 (4·7–9·9) 26 3·9 (2·5–5·7) 0·56 (0·33–0·96) 0·63 (0·36–1·08)
IPD caused by serotypes in PCV10§
<2 months 31 173·2 (117·7–245·8) 0 0·0 Not estimable ··
<5 years 299 60·8 (54·1–68·1) 7 3·2 (1·3–6·5) 0·05 (0·02–0·12) 0·08 (0·03–0·22)
5–14 years 105 13·1 (10·7–15·8) 10 2·5 (1·2–4·6) 0·19 (0·08–0·43) 0·26 (0·11–0·59)
≥15 years 20 4·6 (2·8–7·1) 5 0·7 (0·2–1·7) 0·16 (0·06–0·45) 0·19 (0·07–0·51)
IPD caused by serotypes not in PCV10
<2 months 12 67·0 (34·3–17·0) 1 7·9 (0·2–4·0) 0·12 (0·02–0·94) 0·26 (0·02–3·45)
<5 years 102 20·8 (16·9–25·2) 27 12·2 (8·0–17·7) 0·58 (0·35–0·95) 1·31 (0·65–2·64)
5–14 years 22 2·7 (1·7–4·2) 12 3·0 (1·6–5·3) 1·10 (0·54–2·22) 1·45 (0·66–3·20)
≥15 years 10 2·3 (1·1–4·2) 21 3·1 (1·9–4·8) 1·36 (0·62–2·98) 1·47 (0·67–3·21)
Bacteraemic pneumococcal pneumonia caused by any serotype
<5 years 212 43·1 (37·5–49·3) 19 8·6 (5·2–13·4) 0·20 (0·11–0·35) 0·15 (0·07–0·34)
5–14 years 57 7·1 (5·4–9·2) 11 2·8 (1·4–5·0) 0·38 (0·17–0·86) 0·49 (0·21–1·11)
Pneumococcal meningitis caused by any serotype
<5 years 78 15·9 (12·5–19·8) 3 1·4 (0·3–4·0) 0·08 (0·02–0·29) 0·31 (0·08–1·21)
5–14 years 37 4·6 (3·2–6·4) 4 1·0 (0·3–2·6) 0·21 (0·06–0·71) 0·31 (0·09–1·00)
IPD=invasive pneumococcal disease. KHDSS=Kilifi Health and Demographic Surveillance System. IRR=incidence rate ratio. PCV10=pneumococcal conjugate vaccine. 
*For individuals ≥15 years, the prevaccine era was 2007–10. †IRR estimated using negative binomial regression. ‡IRR estimated using negative binomial regression, 
adjusted for confounding factors significant in the age-specific all-type IPD models: year (age groups <2 months and <5 years), blood culture collection (age groups 
5–14 years and ≥15 years). §PCV serotypes=serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Table 2: Incidence of IPD among children and adults in the KHDSS, in the prevaccine and postvaccine eras
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among those aged 15 years or more (81% reduction, 
95% CI 49–93; adjusted for blood culture ascertainment; 
figure 2; appendix).
Overall 4066 KHDSS residents were enrolled in the 
nasopharyngeal carriage surveys (appendix). VT carriage 
declined among individuals younger than 5 years (with 
significant reductions for serotypes 6B, 19F, and 23F), 
5–14 years, and aged 15 years or more. Non-VT carriage 
increased significantly in in all age groups (table 3; 
appendix). Among children aged less than 5 years, 
carriage of vaccine-related serotype 19A increased; no 
effect on carriage of serotype 6A was observed. In 2016, 
carriage of VT pneumococci was detected in ten (6%) of 
156 children aged less than 5 years, all of whom had 
received three doses of PCV10, and seven (7%) of 
99 children aged 5–14 years, none of whom had received 
PCV10.
In an exploratory post-hoc analysis using negative 
binomial regression, adjusting for calendar-year, the 
introduction of PCV10 was associated with a non-
significant reduction in invasive S aureus disease in 
children aged less than 5 years (IRR 0·65; 95% CI 
0·36–1·18).
Discussion
Using a longstanding, integrated clinical, laboratory, and 
demographic surveillance system, we documented a 
92% reduction in VT-IPD in children younger than 
5 years and substantial indirect protection in Kilifi, Kenya 
following introduction of PCV10 to the routine infant 
immunisation schedule, accompanied by a catch-up 
campaign. Kenya was the first African country to 
include PCV10 in its routine childhood immunisation 
programme. This study provides the first population-
level evidence of a direct and indirect effect of a PCV10 
programme in a low-income country and does not find 
significant evidence of serotype replacement disease in 
the first 6 years of PCV10 use.
Following introduction of PCVs, a large decline in IPD 
was documented in numerous developed world settings; 
however, serotype distributions in carriage and IPD differ 
by geographical area and there have been few opportunities 
to examine PCV10 effect in a developing country.18 In 
Kilifi, we observed a 68% reduction in IPD caused by any 
serotype and a 92% reduction in VT-IPD among children 
younger than 5 years, consistent with findings in middle-
income and high-income settings in which PCV10 or 
PCV13 were used. 4 years after PCV13 introduction, IPD 
was reduced by 64% in US children younger than 5 years 
and 46% in British children younger than 2 years.19,20 
Within the first 3–5 years of PCV13 use, the incidence of 
IPD caused by the six serotypes present in PCV13 but not 
PCV7 declined 93% in US children younger than 5 years, 
80% in Alaska Native children younger than 5 years, 
89% in British children younger than 2 years, and 82% in 
Gambian children aged 2–23 months.19–22 In Latin 
American countries using PCV10 or PCV13, effectiveness 
against VT-IPD has been estimated at 56%–84%.23 
Contributing to the observed reduction in IPD in Kilifi 
were an 85% reduction in bacteraemic pneumococcal 
pneumonia incidence and a 69% reduction in pneumo-
coccal meningitis incidence in children younger than 
5 years. PCV effect on these important clinical out-
comes has been documented elsewhere.24–26 Given that 
the majority of pneumococcal disease is comprised 
Figure 2: Incidence of overall, vaccine-type, and non-vaccine-type invasive pneumococcal disease in the Kilifi 
Health and Demographic Surveillance System, 1999–2016
(A) In individuals aged <5 years. (B) 5–14 years. (C) ≥15 years. Vertical dashed line indicates pneumococcal 
conjugate vaccine introduction. IPD=invasive pneumococcal disease. VT=vaccine serotype.
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of pneumonia, it is notable that PCV10 introduction in 
Kenya was associated with a 27% reduction in childhood 
hospital admissions with clinically-defined pneumonia 
and a 48% reduction in childhood hospital admissions 
with radio logically confirmed pneumonia.27 Although the 
intro duction of PCV10 reduced the overall incidence of 
IPD by 68% in children aged less than 5 years, almost a 
third of serious pneumococcal disease remains. Higher 
valency conjugate vaccines or serotype-independent 
vaccines, which are in development, are likely to lead to 
greater reductions in pneumococcal disease.
In the prevaccine era, IPD was driven by epidemics of 
serotypes 1 and 5 in Kilifi. PCV10 use not only reduced 
the incidence of disease but obliterated IPD epidemics, 
as was also observed in the USA.28 We did not observe a 
reduction in IPD caused by vaccine-related serotypes 6A 
or 19A; this is consistent with the findings from the 
nasopharyngeal carriage surveys in Kilifi. By contrast, an 
analysis of the long-term effect of PCV10 in Finland, 
administered as two primary doses in infancy followed 
by a booster dose (ie, 2 plus 1), documented a reduction 
in IPD caused by serotype 6A but not 19A.29 A case-
control analysis in Brazil, which used a 3 plus 1 schedule 
at the time, documented PCV10 effectiveness against 19A 
but not 6A.30 Data suggest that a booster dose might 
achieve greater protection against vaccine-related 
serotypes but additional studies are required to quantify 
this.31
Notably, we observed protection among infants too 
young to be vaccinated and among older children and 
adults. In South Africa a decline in VT-IPD was noted 
among adults aged 25–44 years within 4 years of PCV7 
introduction.32 However, indirect effects were not 
observed within the 3 years following introduction of 
PCV13 in The Gambia.22 A catch-up campaign was not 
done in The Gambia but in Kilifi this probably accelerated 
population protection.33 The full magnitude of PCV10 
effect might take longer to achieve in the absence of a 
catch-up campaign.
The indirect protection afforded by PCVs is driven by 
the reduction in nasopharyngeal carriage of VT 
pneumococci among vaccinated children. In Kilifi, there 
was a significant reduction in carriage of VT pneumococci 
in both vaccinated and unvaccinated populations within 
6 months of PCV10 introduction.13 However, although 
vaccine-type carriage has declined, VT pneumococci 
continue to be identified in 6% of children aged less than 
5 years and 8% of infants in Kilifi, compared with less 
than 1–2% in other countries that use PCVs.34–38 Residual 
VT carriage has also been documented in other parts of 
Kenya. Among healthy children aged less than 5 years, 
the prevalence of VT carriage ranged between 10% and 
11% in parts of western Kenya that used a catch-up 
campaign and between 4% and 14% in communities 
around Nairobi without catch-up; the difference between 
areas with and without catch-up could not be 
distinguished statistically.39,40 The persistence of VT 
carriage might reflect a higher force of infection in Kenya 
and it indicates continued risk for VT-IPD in unvaccinated 
or under-vaccinated children, and adults.41 Another 
possible explanation for persistent VT carriage is that, 
unlike most middle-income and high-income countries, 
Kenya introduced PCV10 without a booster dose in the 
second year of life. Many low-income countries have 
introduced PCV with three primary doses without a 
booster (3 plus 0 schedule), and it will be important to 
establish whether the absence of a booster dose, which 
might lead to more rapid waning of immunity, leads to a 
persistent transmission reservoir, vaccination failures, or 
rebound disease incidence. An analysis of the PCV 
vaccination programme in Australia suggested waning 
effectiveness, particularly beyond 24 months after the 
third dose, and suboptimal community protection with a 
3 plus 0 schedule.42 These findings led the Australian 
National Immunisation Technical Advisory Group to 
recommend a change in the PCV schedule to include a 
booster dose.43
In addition to persistent VT carriage, we also observed 
a 71% increase in carriage of non-VT pneumococci 
(particularly serotype 19A) in children younger than 
5 years. The PCV-associated decline in VT carriage and 
corresponding increase in non-VT carriage has been well 
described. Although an increase in non-VT IPD disease 
has been reported in settings that use expanded valency 
PCVs, the increases have generally been small compared 
with the decline in VT-IPD.19,20 A significant increase in 
non-VT IPD in adults has offset the benefits of PCV use 
in some settings such as the UK and Brazil; however, 
enhanced surveillance in the postvaccine period might 
account for some of this increase in Brazil.44,45 Although 
our surveillance for non-VT IPD did not detect a 
Carriage 
prevalence 
prevaccine era 
(2009–10) n (%)
Carriage 
prevalence 
postvaccine era 
(2012–16) n (%)
Crude prevalence 
ratio (95% CI)
Age-standardised 
adjusted prevalence 
ratio (95% CI)*
All S pneumoniae
<5 years 229 (74·4%) 606 (76·0%) 1·02 (0·95–1·10) 1·00 (0·92–1·08)
5–14 years 103 (52·6%) 237 (48·5%) 0·92 (0·78–1·08) 0·96 (0·81–1·13)
≥15 years 123 (24·0%) 287 (22·8%) 0·95 (0·79–1·14) 1·00 (0·81–1·22)
Vaccine-type S pneumoniae
<5 years 104 (33·8%) 70 (8·8%) 0·26 (0·20–0·34) 0·26 (0·19–0·35)
5–14 years 30 (15·3%) 29 (5·9%) 0·39 (0·24–0·63) 0·38 (0·22–0·64)
≥15 years 29 (5·7%) 17 (1·4%) 0·24 (0·13–0·43) 0·23 (0·12–0·44)
Non-vaccine-type S pneumoniae
<5 years 125 (40·6%) 557 (69·9%) 1·72 (1·49–1·99) 1·71 (1·47–1·99)
5–14 years 73 (37·2%) 216 (44·2%) 1·19 (0·96–1·46) 1·25 (1·01–1·54)
≥15 years 94 (18·3%) 286 (22·7%) 1·24 (1·01–1·53) 1·30 (1·05–1·63)
*Models adjusted for number of children aged <10 years in household, month of swab collection, cough or rhinorrhea 
in preceding 14 days (all age groups); antibiotic use in the preceding 14 days also remained in the model for children 
aged 5–14 years.
Table 3: Carriage prevalence and prevalence ratios for nasopharyngeal carriage of Streptococcus 
pneumoniae in the prevaccine and postvaccine eras
Articles
8 www.thelancet.com   Published online April 15, 2019   http://dx.doi.org/10.1016/S0140-6736(18)33005-8
significant increase in any age group, the direction of 
change was positive in all age groups 2 months and 
above (IRRs 1·31–1·47). Given the low baseline incidence 
of non-VT IPD, comprising only one quarter of the 
prevaccine burden of IPD among children aged less than 
5 years, the power of the study was only sufficient (ie, 
>80%) to detect at least a 2·3-fold change (appendix). The 
small relative increase that was observed did not translate 
into a significant absolute rise in incidence. To clarify 
these emerging trends, it will be important to continue to 
monitor children and adults for pneumococcal disease in 
the existing surveillance setting for several years to come. 
Not only is this essential to detect possible emergence of 
non-VT disease, but also to monitor for rebound VT 
disease that might occur if the indirect effects achieved 
by the catch-up campaign wane in the absence of booster 
dose to sustain immunity and suppress circulation of VT 
pneumococci.
The before–after study design, which is the principal 
method for evaluation of the population effect of 
vaccines, has inherent weaknesses. In Kilifi, general 
health improved slowly over the surveillance period. The 
incidence of hospital admissions for various illnesses 
declined. The reduction in non-VT IPD over time among 
infants aged less than 2 months, by contrast with the rise 
in older age groups, suggests specific improvements in 
maternity services and infant care. The incidence of HIV 
in the population has not been systematically measured 
and was not included in the analysis; however, the 
prevalence of HIV among women seeking antenatal care 
was less than 5% over the surveillance period and it is 
therefore unlikely that changes in HIV incidence would 
have significantly confounded estimates of vaccine 
effectiveness. Several factors argue that the observed 
reduction in IPD in Kilifi is attributable to the 
introduction of PCV10, although the exact estimate of 
effect might be subject to some residual confounding in 
the variables mentioned above. Consistent surveillance 
methods were used over a long period of time and 
changes in VT-IPD occurred abruptly at the same time as 
vaccine introduction with a catch-up campaign, and 
simultaneously with marked changes in VT carriage 
prevalence. Systematically collected data on a wide range 
of possible confounders were included in the analysis.
Pneumococcal disease remains a leading vaccine-
preventable cause of childhood mortality, and most of 
these deaths occur in Africa. To date, 141 countries, 
including 58 Gavi-eligible countries, have introduced a 
PCV into their national childhood immunisation 
programmes.3 16 countries are in the process of tran-
sitioning out of Gavi support and five have reached the 
end of Gavi support. The PCV programme is the most 
expensive component of the national immunisation 
schedule and the sustainability of PCV vaccination in low-
income countries will depend on the demonstrable effect 
of PCV in reducing childhood morbidity and mortality. 
Because of the necessity for stable prevaccine surveillance, 
evaluations of PCV effect are rare in Africa. On the basis 
of this carefully standardised, prospectively designed, 
18-year surveillance study, we conclude that use of PCV10 
in tropical Africa will lead to substantial health benefits 
for the whole population. Continued surveillance will 
elucidate the long-term sustainability of these benefits.
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